We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+6.45%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.23B
AUM Growth
+$1.54B
Cap. Flow
+$1.36B
Cap. Flow %
42.13%
Top 10 Hldgs %
68.77%
Holding
142
New
24
Increased
22
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$1.32B
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$73.7M
3
SLRN
ACELYRIN
SLRN
+$37.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.3M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$61.1M
2
ONC
BeOne Medicines Ltd
ONC
+$20.5M
3
FATE icon
Fate Therapeutics
FATE
+$14.8M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.3M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 54.66%
2 Consumer Discretionary 41.39%
3 Miscellaneous 3.23%
4 Technology 0.24%
5 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUPH icon
51
Aurinia Pharmaceuticals
AUPH
$2.14B
$9.68M 0.3%
1,000,000
– –
SLN
52
Silence Therapeutics
SLN
$812M
$9.35M 0.29%
1,700,000
+1,194,926
+237% +$7.21M
DYN icon
53
Dyne Therapeutics
DYN
$3.46B
$9.17M 0.28%
815,085
+282,476
+53% +$3.33M
MRTX
54
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$9.03M 0.28%
+250,000
New +$10.3M
VOR icon
55
Vor Biopharma
VOR
$1.37B
$8.31M 0.26%
134,401
-5,239
-4% -$478K
OVID icon
56
Ovid Therapeutics
OVID
$535M
$8.2M 0.25%
2,500,000
– –
FUSN
57
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$8.06M 0.25%
1,725,000
-250,000
-13% -$1.08M
RPTX
58
DELISTED
Repare Therapeutics
RPTX
$7.41M 0.23%
700,000
– –
FOLD
59
CALL
DELISTED
Amicus Therapeutics
FOLD
$6.28M 0.19%
+500,000
New +$5.93M
DAWN
60
DELISTED
Day One Biopharmaceuticals
DAWN
$5.97M 0.19%
+500,000
New +$6.53M
ARAV
61
DELISTED
Aravive, Inc. Common Stock
ARAV
$5.76M 0.18%
4,572,515
– –
MORF
62
CALL
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.73M 0.18%
+100,000
New +$5.22M
VERV
63
DELISTED
Verve Therapeutics
VERV
$5.63M 0.17%
300,000
– –
ITOS
64
DELISTED
iTeos Therapeutics
ITOS
$5.3M 0.16%
400,000
– –
BEKE icon
65
KE Holdings
BEKE
$18.4B
$5.2M 0.16%
350,000
+75,000
+27% +$1.22M
NBTX
66
Nanobiotix
NBTX
$1.82B
$5.07M 0.16%
1,000,000
– –
HOOK
67
DELISTED
HOOKIPA Pharma
HOOK
$4.99M 0.15%
566,641
+381,679
+206% +$4.24M
SLDB icon
68
Solid Biosciences
SLDB
$937M
$4.76M 0.15%
909,219
– –
SYRS
69
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.65M 0.14%
1,475,744
– –
TSM icon
70
TSMC
TSM
$2.17T
$4.29M 0.13%
42,500
+12,500
+42% +$1.16M
PFTA
71
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.94M 0.12%
380,000
– –
ALXO icon
72
ALX Oncology
ALXO
$268M
$3.75M 0.12%
500,000
– –
GOSS icon
73
Gossamer Bio
GOSS
$65.4M
$3.63M 0.11%
37,852
– –
LCID icon
74
Lucid Motors
LCID
$1.64B
$3.38M 0.1%
+49,000
New +$3.5M
RNAM
75
DELISTED
Avidity Biosciences
RNAM
$3.33M 0.1%
300,000
-211,962
-41% -$2.66M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2023 Portfolio in Review

As of Q2 2023, Artal Group held 142 positions worth $3.23B, up 92% from $1.68B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group deployed $1.36B of net new capital in Q2 2023, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was CAVA Group: 32,007,990 shares worth $1.31B.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 94% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $20.5M trimmed.

  • Artal Group's largest Q2 2023 buy was CAVA Group: 32,007,990 shares worth $1.31B.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2023, an estimated $73.7M increase.
  • Artal Group's biggest Q2 2023 reduction was BeOne Medicines Ltd, cutting an estimated $20.5M.
  • Artal Group fully exited WW International in Q2 2023, selling an estimated $61.1M.
  • Artal Group's ten largest holdings make up 69% of its $3.23B portfolio in Q2 2023.
  • Artal Group opened 24 new positions and closed 25 in Q2 2023.
  • Artal Group's portfolio value rose 92% quarter-over-quarter to $3.23B.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.